Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Articles published by Xencor, Inc.
< Previous
1
2
Next >
Xencor to Present at Upcoming Investor Conferences
November 10, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting
November 10, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Reports Third Quarter 2022 Financial Results
November 07, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study
November 07, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting
November 03, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022
October 31, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting
October 05, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Appoints Nancy Valente, M.D., to Board of Directors
September 09, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Reports Second Quarter 2022 Financial Results
August 03, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022
July 27, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors
May 26, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Reports First Quarter 2022 Financial Results
May 05, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022
April 28, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022
April 08, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Reports Fourth Quarter and Full Year 2021 Financial Results
February 23, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022
February 16, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present at Upcoming Investor Conferences
February 02, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones
January 11, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference
January 06, 2022
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting
December 12, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor
November 21, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present at Upcoming Investor Conferences
November 19, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting
November 12, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306
November 08, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting
November 04, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium
November 03, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Present at Upcoming Investor Conferences
November 02, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021
November 01, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies
October 04, 2021
From
Xencor, Inc.
Via
Business Wire
Tickers
XNCR
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.